Science Translational Medicine
18 September 2019 Vol 11, Issue 510
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa
By Glenda E. Gray, Ying Huang, Nicole Grunenberg, Fatima Laher, Surita Roux, Erica Andersen-Nissen, Stephen C. De Rosa, Britta Flach, April K. Randhawa, Ryan Jensen, Edith M. Swann, Linda-Gail Bekker, Craig Innes, Erica Lazarus, Lynn Morris, Nonhlanhla N. Mkhize, Guido Ferrari, David C. Montefiori, Xiaoying Shen, Sheetal Sawant, Nicole Yates, John Hural, Abby Isaacs, Sanjay Phogat, Carlos A. DiazGranados, Carter Lee, Faruk Sinangil, Nelson L. Michael, Merlin L. Robb, James G. Kublin, Peter B. Gilbert, M. Juliana McElrath, Georgia D. Tomaras, Lawrence Corey
Science Translational Medicine18 Sep 2019 Full Access
In South Africans, the RV144 HIV vaccine regimen elicited robust immune responses that have been associated with vaccine efficacy.
Taking RV144 beyond Thailand
The RV144 vaccine trial in Thailand is the only HIV vaccine to show efficacy against HIV infection to date. Gray et al. designed the HVTN 097 trial to test this regimen in South Africa, where clade C HIV circulates; this clade is heterologous to the vaccine antigens. They intently examined immune protective responses previously identified in the RV144 trial and found that the vaccine seemed to be even more immunogenic in South Africans. CD4+ T cell responses were stronger and more common in HVTN 097, and the magnitude of protective antibody responses was greater compared to RV144. Their results indicate that the RV144 regimen or others like it could be protective in areas where HIV is endemic.